Theracryf Plc (AIM:TCF)

London flag London · Delayed Price · Currency is GBP · Price in GBX
0.2550
-0.0060 (-2.35%)
Jun 17, 2025, 4:35 PM GMT+1
-73.85%
Market Cap 5.43M
Revenue (ttm) n/a
Net Income (ttm) -1.94M
Shares Out 2.13B
EPS (ttm) -0.00
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 1,557,954
Average Volume 3,598,385
Open 0.2480
Previous Close 0.2550
Day's Range 0.2480 - 0.2800
52-Week Range 0.2000 - 1.2500
Beta 1.27
RSI 51.43
Earnings Date May 28, 2025

About Theracryf

Theracryf Plc, a clinical stage therapeutics company, engages in the development of therapeutics for oncology and behavioral brain disorders. The company’s lead product is SFX-01 that is in Phase II clinical trials for the treatment of metastatic breast cancer; and in Phase I clinical trials for the treatment of neurodevelopmental disorders and glioblastoma, as well as in preclinical stage for the treatment of rhabdomyosarcoma. In addition, it engages in the development of orexin 1 antagonist, which is in late preclinical stage targeting addict... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2014
Employees 9
Stock Exchange London Stock Exchange AIM
Ticker Symbol TCF
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.